RBC Capital analyst Joseph Spak downgrades Adient (NYSE:ADNT) from Outperform to Sector Perform and announces $36 price target.
High-Profile Highs: How Celebrity Advocacy Is Transforming Society’s Views On Psychedelics And Cannabis
As part of the recent so-called “psychedelics renaissance,” numerous celebrities, global